Medical device developer Boston Scientific ( BSX) said it received clearance from the Food and Drug Administration to market its saphenous vein graft, or SVG, disease treatment.

The company's FilterWire EX Embolic Protection System will be launched next week in the U.S. SVG disease occurs when saphenous veins harvested from the leg for use in coronary artery bypass graft surgery develop atherosclerosis.

Shares of the company were up 0.7% at $56.43 in late morning trading Monday.